| payload |
{"created_at":"2026-04-20T17:15:12.787 {"created_at":"2026-04-20T17:15:12.787981+00:00","dedupe_key":"signal_enriched:discovery_unusual_volume_delta:3bb4b1ed6f9d1992","evidence_event_ids":["evt_8eec1438a2d5"],"signal_type":"discovery_unusual_volume_delta","source":"discovery_ingestor","value":{"aggregator_url":"https://www.nasdaq.com/articles/why-compass-pathways-stock-rocketed-40-today","as_of":"2026-04-20T17:15:12.787981+00:00","canonical_url":"https://www.fool.com/investing/2026/04/20/why-compass-pathways-stock-rocketed-30-today/","enrichment":{"aggregator_url":"https://www.nasdaq.com/articles/why-compass-pathways-stock-rocketed-40-today","article_chars":3355,"article_truncated":false,"blocked_reason":null,"candidate_id":"sc_66dbc6f482201524","canonical_host":"fool.com","canonical_is_aggregator":false,"canonical_url":"https://www.fool.com/investing/2026/04/20/why-compass-pathways-stock-rocketed-30-today/","content_type":"text/html; charset=utf-8","enriched_at":"2026-04-21T03:05:41.604393+00:00","extraction_method":"trafilatura","fetched_description":"Key PointsCompass Pathways has already reported two positive phase 3 trials for treatment-resistant depression (TRD).","fetched_title":"Why Compass Pathways Stock Rocketed 40% Today | Nasdaq","final_url":"https://www.nasdaq.com/articles/why-compass-pathways-stock-rocketed-40-today","html_truncated":false,"paywall_likely":false,"publisher_domain":"fool.com","publisher_resolution":"canonical_url","requested_url":"https://www.nasdaq.com/articles/why-compass-pathways-stock-rocketed-40-today","source_event_id":"evt_8eec1438a2d5","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"fp":"f02be8d4f1a08f91","kind":"unusual_volume","published_at":"2026-04-20T16:22:35+00:00","publisher_domain":"fool.com","signal_understanding":{"analysis_basis":"article","claim_confidence":0.74,"dates_mentioned":["not specified (intraday; noon ET referenced)"],"entities":[{"asset_class":"equity","name":"Compass Pathways Plc","relevance":"high","symbol":"CMPS","type":"company"},{"asset_class":"other","name":"COMP360","relevance":"high","symbol":"","type":"drug_program"},{"asset_class":"other","name":"White House Executive Order","relevance":"high","symbol":"","type":"policy_event"},{"asset_class":"other","name":"U.S. Food and Drug Administration (FDA)","relevance":"medium","symbol":"","type":"regulator"},{"asset_class":"other","name":"Kabir Nath","relevance":"medium","symbol":"","type":"person"}],"event_type":"macro_policy","information_gaps":["Unusual volume ratio vs average is not provided in the text (baseline volume and volume_ratio are missing).","The signal type is 'discovery_unusual_volume_delta', but the article excerpt does not explicitly confirm unusual volume or provide volume metrics.","The exact executive order date/time and whether the move is causally confirmed by news/market data are not explicitly established in the provided text.","No specific catalyst timing link (e.g., EO release time vs market open) is provided beyond 'over the weekend' and 'today' language."],"key_facts":["The article states Compass Pathways (NASDAQ: CMPS) rocketed more than 50% this morning and was still higher by 41.2% at noon ET.","The article says Compass has already reported two positive Phase 3 trials for treatment-resistant depression (TRD).","The article describes COMP360 as a synthetic psilocybin treatment.","The article says a White House executive order seeks to accelerate innovative research models and appropriate drug approvals to increase access to psychedelic drugs for serious mental illness.","The article quotes Compass CEO Kabir Nath praising the executive order and stating it aligns regulatory urgency with patient need.","The article states Compass is already working with the FDA toward submission for approval."],"numeric_claims":[{"label":"intraday_gain_this_morning_percent","value":"more than 50%"},{"label":"gain_at_noon_ET_percent","value":"41.2%"}],"primary_claim":"Compass Pathways shares rose sharply on the day of a White House executive order, with the article attributing the rally to expectations that its COMP360 synthetic psilocybin could get an accelerated approval pathway after positive Phase 3 trials.","relevance_score":0.72,"sentiment":"positive","source_quality":"high","summary":"Compass Pathways (NASDAQ: CMPS) surged intraday (reported as more than 50% this morning and 41.2% higher at noon ET) alongside a White House executive order aimed at accelerating psychedelic drug approvals. The article links the move to investor optimism that Compass\u2019s COMP360 synthetic psilocybin could move faster toward approval after prior positive Phase 3 results.","topics":["psychedelic drugs","treatment-resistant depression","Phase 3 trials","regulatory acceleration","executive order","stock price surge","COMP360"]},"source":"Nasdaq Markets","source_domain":"fool.com","summary":"Key PointsCompass Pathways has already reported two positive phase 3 trials for treatment-resistant depression (TRD).","tickers":["TRD"],"title":"Why Compass Pathways Stock Rocketed 40% Today","url":"https://www.fool.com/investing/2026/04/20/why-compass-pathways-stock-rocketed-30-today/"}}... |